Michelle Carr, Author at BioTuesdays

Developments

IntelGenx updates Montelukast VersaFilm collaboration for Parkinson’s

IntelGenx (TSX:IGX; OTCQB:IGXT) finalized a research grant agreement with Sweden’s Karolinska University Hospital and that the manufacturing of both active and placebo films are underway for a planned multicentre...

July 25, 2023

Developments

Infinity terminates merger accord with MEI Pharma

Infinity Pharmaceuticals (NASDAQ:INFI) terminated its merger agreement to merge with MEI Pharma (NASDAQ:MEIP). At a special meeting of MEI stockholders on July 23, MEI did not obtain stockholder approval for the merger...

July 24, 2023

Developments

Advent nabs rare pediatric disease designation for bronchopulmonary dysplasia in preemies

Advent Therapeutics received FDA rare pediatric disease designation for its vitamin A metabolic and reparative respiratory drugs for the prevention of bronchopulmonary dysplasia (BPD) in premature infants. BPD is a rare...

July 20, 2023

Developments

MindBio pre-screening patients in take-home LSD-microdosing Phase 2 study

MindBio Therapeutics Corp (CSE:MBIO; Frankfurt:WF6) started pre-screening for participant entry into Phase 2 LSD-microdosing clinical trials. The clinical trials are a world first with approvals for take home use of...

July 19, 2023

Developments

Anixa Biosciences breast cancer vaccine featured in Daily Mail article

A Phase 1 trial of Anixa Biosciences’ (NASDAQ:ANIX) breast cancer vaccine and women survivors were featured in an article on the website of England’s Daily Mail newspaper. Anixa’s CEO, Amit Kumar, Ph.D., described the...

July 17, 2023

Developments

Ondine receives TAYYABA HASAN IMPACT AWARD at IPA World Congress

Ondine Biomedical (LON:OBI) was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association (IPA) in Finland for demonstrating “exceptional perseverance and clinical...

July 17, 2023

Developments

FDA clears Tryp’s IND for Phase 2a IBS study at MGH

The FDA completed a review of Tryp Therapeutics’ (CSE:TRYP; OTCQB:TRYPF) investigational new drug application, permitting the company to proceed with a Phase 2a clinical trial at Massachusetts General Hospital (MGH)...

July 13, 2023

Executive Moves

Former Pfizer vaccine president Nanette Cocero joins PharmaJet board

PharmaJet appointed Nanette Cocero, Ph.D., a recognized leader in the global pharmaceutical industry with broad commercial and business experience coupled with an extensive clinical and scientific background, to the...

July 12, 2023

Developments

Anixa Biosciences receives Canadian patent for CAR-T cancer therapy technology

The Canadian Intellectual Property Office issued a patent covering Anixa Biosciences’ (NASDAQ:ANIX) novel chimeric antigen receptor T-cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar...

July 11, 2023

Developments

ZyVersa receives European patent for VAR 200 in kidney disease

The European Patent Office granted a patent covering ZyVersa Therapeutics’ (NASDAQ:ZVSA) Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease. “Approval of this...

July 7, 2023

Author - Michelle Carr

IntelGenx updates Montelukast VersaFilm collaboration for Parkinson’s

Infinity terminates merger accord with MEI Pharma

Advent nabs rare pediatric disease designation for bronchopulmonary dysplasia in preemies

MindBio pre-screening patients in take-home LSD-microdosing Phase 2 study

Anixa Biosciences breast cancer vaccine featured in Daily Mail article

Ondine receives TAYYABA HASAN IMPACT AWARD at IPA World Congress

FDA clears Tryp’s IND for Phase 2a IBS study at MGH

Former Pfizer vaccine president Nanette Cocero joins PharmaJet board

Anixa Biosciences receives Canadian patent for CAR-T cancer therapy technology

ZyVersa receives European patent for VAR 200 in kidney disease

Subscribe